Share This Page
Litigation Details for Swissdigital USA Co., Ltd. v. Samsonite Group S.A. (D. Mass. 2024)
✉ Email this page to a colleague
Swissdigital USA Co., Ltd. v. Samsonite Group S.A. (D. Mass. 2024)
| Docket | ⤷ Start Trial | Date Filed | 2024-06-25 |
| Court | District Court, D. Massachusetts | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Julia E. Kobick |
| Jury Demand | Both | Referred To | Paul G. Levenson |
| Patents | 10,047,053; 11,040,006; 11,040,029; 11,097,006; 12,005,036; 12,005,051; 12,005,052; 9,022,022; 9,062,014 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Swissdigital USA Co., Ltd. v. Samsonite Group S.A.
Details for Swissdigital USA Co., Ltd. v. Samsonite Group S.A. (D. Mass. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-06-25 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Swissdigital USA Co., Ltd. v. Samsonite Group S.A., 1:24-cv-11636: Litigation Summary, Claims, Timeline, and Risk Analysis
Swissdigital USA Co., Ltd. sued Samsonite Group S.A. in U.S. District Court under docket 1:24-cv-11636. The case is pending and, based on the docket label and public posture, Swissdigital’s asserted rights appear to relate to technology and/or product features tied to Swissdigital’s portfolio. The litigation is at an early stage, with limited public record on claim construction and merits determinations.
What is Swissdigital USA Co., Ltd. v. Samsonite Group S.A., 1:24-cv-11636 about?
Answer: The lawsuit is a federal civil action filed in 2024 against Samsonite Group S.A. by Swissdigital USA Co., Ltd., alleging infringement of Swissdigital’s intellectual property (exact asserted IP rights and claim elements are not fully visible in the public snippet-level information).
What court and procedural posture does 1:24-cv-11636 have?
- Case: Swissdigital USA Co., Ltd. v. Samsonite Group S.A.
- Docket number: 1:24-cv-11636
- Year filed: 2024
- Status: Pending (no merits ruling shown in the limited public materials available for this docket summary).
What issues are typically at stake in this kind of IT/product-feature IP case?
While the specific asserted patents/claims are not enumerated in the snippet-level docket information available here, actions involving product-feature or technology-IP are usually structured around:
- infringement of one or more asserted patents (or other IP rights),
- validity challenges (if patent-based),
- willfulness or enhanced damages theories (if supported),
- injunctive relief and/or damages.
What are the asserted rights and how do they typically map to infringement allegations?
Answer: Swissdigital’s complaint alleges Samsonite’s conduct infringes Swissdigital’s protected rights, which likely correspond to specific product functionality or design elements. The exact claim chart is not available in the limited public record for this docket summary.
Patent-based mapping: what the pleadings usually require
If the case is patent-centric, a typical complaint includes:
- a list of asserted patents,
- identification of accused products,
- claim-by-claim infringement allegations,
- allegations supporting direct infringement and possibly inducement/contributory infringement,
- venue and infringement bases.
Non-patent mapping: if it is trade secret, copyright, or trademark
If the complaint asserts non-patent IP:
- trade secrets: misappropriation and “reasonable measures” allegations,
- copyright: protectable subject matter and copying,
- trademark: likelihood-of-confusion and use in commerce allegations.
What is the litigation timeline for 1:24-cv-11636?
Answer: The case was filed in 2024. The public record provided with this prompt does not include a full order-by-order chronology.
Key phases that would normally appear in the docket
- Complaint and service
- Responsive pleading (motion to dismiss or answer)
- Scheduling order
- Claim construction / Markman (patent cases)
- Discovery (technical documents, source files, product testing, sales and marketing records)
- Dispositive motions
- Pretrial orders
- Trial or settlement
What filings matter most early in 1:24-cv-11636?
Answer: The most outcome-determinative early-stage filings in IP cases are typically:
- motions to dismiss for lack of jurisdiction, failure to state a claim, or defective pleading,
- early case management orders that shape discovery and claim scope,
- any request for preliminary injunction or expedited discovery (if the complaint sought it).
How does the pleading stage affect settlement leverage?
- If Swissdigital’s asserted claims are broad and directly tied to specific Samsonite SKUs, Swissdigital usually gains earlier leverage for a settlement.
- If Samsonite targets claim scope via early motions or narrowing constructions, leverage can shift to Samsonite before discovery closes.
What patents and claims are involved in Swissdigital’s case?
Answer: The asserted patent numbers (or other right identifiers) are not listed in the information provided for this docket-level request.
What you would normally extract for analysis (but cannot from the provided snippet)
- asserted patent publication numbers,
- priority dates,
- claim categories (apparatus, method, system, computer-implemented steps),
- expiration windows,
- prosecution history estoppel risks,
- claim construction vulnerabilities.
How likely is early dismissal or narrowing in Swissdigital v. Samsonite?
Answer: The likelihood cannot be assessed from the provided snippet-level docket content because the record does not include:
- the grounds raised in any motion,
- the court’s rulings,
- the specific infringement theories pleaded.
What defendants usually argue in early motions
- jurisdictional and standing defects,
- failure to identify an infringement theory with sufficient specificity,
- indefiniteness or failure to state a plausible infringement case,
- if patent-based: inadequate description of how accused products meet each limitation.
Is this case likely to end in a settlement? What drives the settlement range?
Answer: Settlement is often the dominant endpoint in early-stage IP cases because discovery costs, injunction risk, and uncertainty around claim construction create asymmetric exposure. However, the prompt-provided docket information does not include mediation orders, settlement communications, or claim scope indicators.
Settlement drivers in product-feature IP
- strength of Swissdigital’s technical narrative against real Samsonite product features,
- whether the accused products are commercially significant,
- the availability of non-infringing alternatives,
- injunction likelihood given irreparable harm allegations (if any).
What damages theories and remedies are typically sought against Samsonite in cases like this?
Answer: The complaint likely seeks some combination of damages and injunctive relief, but the specific remedies pleaded are not visible in the provided snippet.
Remedies that frequently appear
- injunction against continued manufacture/sale,
- damages (reasonable royalty, lost profits if proven),
- enhanced damages if willfulness is pled and supported,
- attorneys’ fees if exceptional-case standards are met.
How does this case impact Samsonite’s product roadmap and IP clearance?
Answer: Even before a merits ruling, a pending infringement case typically triggers:
- product-design review and claim-scope mapping,
- freedom-to-operate assessments,
- supplier and software stack audits (if technology claims are involved),
- potential rebranding or feature redesign to reduce exposure.
Where risk concentrates
- active sales channels for accused models,
- feature updates that overlap with the accused functionality,
- marketing materials that may support inducement or direct infringement narratives.
What is the Orange Book / Hatch-Waxman relevance for this docket?
Answer: The Swissdigital v. Samsonite docket does not indicate Hatch-Waxman, Orange Book, or FDA exclusivity issues.
When Orange Book becomes relevant (not shown here)
Orange Book and Paragraph IV frameworks apply to small molecules and some therapeutics with FDA ANDA challenges. This Samsonite matter, as framed, is not an FDA-driven generic exclusivity dispute based on the provided docket context.
What jurisdictions and service reach matter for enforcement?
Answer: The enforcement and litigation footprint are U.S.-federal, with remedies enforceable against Samsonite’s U.S. operations and sales into the U.S.
Practical enforcement levers
- injunctive relief binding on parties and their agents,
- discovery into U.S. sales, distribution, and marketing,
- subpoenas for key affiliates, retailers, and manufacturing partners.
How strong is Swissdigital’s patent estate (or other IP position)?
Answer: Cannot be determined from the limited information provided in the prompt, which does not include asserted right identifiers, claim scope, prior art landscape, or prosecution history.
What would normally be analyzed to grade strength
- number of asserted claims and overlap with accused products,
- claim breadth versus prior art,
- litigation history and claim construction outcomes,
- licensing posture and market exclusivity,
- technical evidence: prototypes, documents, internal design decisions.
What generic entry risks exist for Swissdigital’s case?
Answer: None. This is not a drug regulatory exclusivity or generic entry scenario based on the docket framing provided.
What is the competitive landscape and who else is at risk?
Answer: The prompt provides no co-defendants, related suits, or industry participants in the 1:24-cv-11636 matter.
Typical spillover pathways
- downstream resellers and distributors of accused products,
- component suppliers implicated by infringement theories,
- affiliates that develop regional product variants.
What should an investor or licensing team watch next in 1:24-cv-11636?
Answer: For pending IP cases, the next business-critical signals are:
- early motion outcomes (dismissal, claim narrowing),
- claim construction dates and any Markman rulings,
- emergency relief orders if an injunction is sought,
- discovery scope and expert schedules.
Decision checkpoints
- If early narrowing reduces claim coverage, licensing value often drops.
- If the court keeps broad claim scope, settlement leverage and damages exposure increase.
Key Takeaways
- Swissdigital USA Co., Ltd. v. Samsonite Group S.A. is a pending federal case in 1:24-cv-11636, filed in 2024.
- The provided docket-level information does not include the asserted IP identifiers (e.g., patent numbers) or any merits rulings, limiting claim-by-claim strength and validity analysis.
- Business impact will likely center on product-feature clearance, design-around review, and settlement leverage once early procedural motions and any claim construction steps occur.
FAQs
1) What court handled Swissdigital USA Co., Ltd. v. Samsonite Group S.A. (1:24-cv-11636)?
It is a U.S. district court action under the docket number 1:24-cv-11636.
2) Has Swissdigital won any motions in 1:24-cv-11636?
No merits motion outcomes are shown in the information provided.
3) What damages and injunction targets are typical in a Swissdigital-style IP product case?
Common requests include damages (royalty or lost profits) and injunctive relief, but the specific remedies pleaded are not visible in the provided docket snippet.
4) Does this case relate to FDA Orange Book or Hatch-Waxman exclusivity?
Nothing in the provided docket context indicates an FDA/Orange Book exclusivity dispute.
5) What are the next milestones that usually drive settlement in pending IP suits?
Early motions, scheduling orders, discovery scope, and any claim construction steps (if patent-based).
References
- U.S. District Court docket for Swissdigital USA Co., Ltd. v. Samsonite Group S.A., 1:24-cv-11636.
More… ↓
